Inavolisib lengthens progression-free survival time in HER2-negative advanced breast cancer

1. In this randomized controlled trial, in patients with PIK3CA-mutated advanced breast cancer, the addition of inavolisib to a palbociclib-fulvestrant regimen significantly extended progression-free survival compared to palbociclib-fulvestrant alone. 2. The addition of inavolisib did not significantly increase the overall occurrence of adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Locally advanced or metastatic […]